asd
asd
暂无个人介绍
IP属地:湖南
34关注
0粉丝
0主题
0勋章
avatarasd
2017-02-09
$Naked Brand Group Inc(NAKD)$这盘前很会玩啊
avatarasd
2016-11-29
$达泰莱(DRAM)$昨天卖了………………
avatarasd
2016-11-21
$Opexa Therapeutics(OPXA)$有入的吗有进场的吗
avatarasd
2016-10-17
$天人果汁(SPU)$要退市了为什么才跌这么点
avatarasd
2016-10-14
$MGT Capital Investments(MGT)$会破3吗
avatarasd
2016-08-23
$Amedica Corp(AMDA)$有人买吗
avatarasd
2016-08-17
$StemCells(STEM)$666
avatarasd
2016-08-05
$SAExploration Holdings Inc.(SAEX)$这尼玛谁敢买
avatarasd
2016-08-05
$Zynerba Pharmaceuticals, Inc.(ZYNE)$稳步增长
avatarasd
2016-08-05
$SAExploration Holdings Inc.(SAEX)$47.5卖了
avatarasd
2016-07-25
$天人果汁(SPU)$ 我星期五盘后给卖了 唉
avatarasd
2016-07-01
$奥星制药(BSPM)$有做的吗
avatarasd
2016-06-15
$Cellectar Biosciences Inc.(CLRB)$StreetInsiderCellectar Biosciences (CLRB) Announces Positive Prelim. Results for CLR 1602 in Tumor TargetingJune 15, 2016 8:34 AM Cellectar Biosciences, Inc. (Nasdaq: CLRB) announces the results of a preliminary tumor-targeting study that shows its prototype paclitaxel chemotherapeutic conjugate, CLR 1602, may be up to 30 times more tumor selective in comparison to free paclitaxel.The preliminary in vivo study demonstrated that tumor uptake of CLR 1602’s paclitaxel payload increased by more than 30-fold over free paclitaxel, and also displayed an extended plasma half-life relative to free paclitaxel. The extended plasma half-life may, in part, explain the enhanced tumor uptake. Unlike free paclitaxel, which was rapidly cleared from plasma within 24 hours,
avatarasd
2016-06-08
$奥星制药(BSPM)$ 有什么利好吗
avatarasd
2016-06-08
$Bridgeline Digital(BLIN)$有成交的没 为什么我的一直都不成交
avatarasd
2016-06-08

盘前可以做空吗

$Helios and Matheson Information(HMNY)$盘前可以做空吗
盘前可以做空吗
avatarasd
2016-06-07
$Aehr Test Systems(AEHR)$ 没人买吗

去老虎APP查看更多动态